Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

@article{Kristensen2019CardiovascularMA,
  title={Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.},
  author={S. Kristensen and Rasmus R{\o}rth and P. Jhund and K. Docherty and N. Sattar and D. Preiss and L. K{\o}ber and M. Petrie and J. McMurray},
  journal={The lancet. Diabetes \& endocrinology},
  year={2019}
}
BACKGROUND Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their structure and duration of action and have been studied in trials of varying sizes and with different patient populations, with inconsistent effects on cardiovascular outcomes reported. We aimed to synthesise the available evidence by doing a systematic review and meta-analysis of cardiovascular outcome trials of these drugs. METHODS We searched MEDLINE (via PubMed) and the Cochrane Central Register of Controlled… Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 27 REFERENCES
Liraglutide and Renal Outcomes in Type 2 Diabetes
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
...
1
2
3
...